Oral abrocitinib 'effective' for teens with atopic dermatitis

Results from a phase 3 trial of the investigational JAK-1 selective inhibitor

The investigational drug oral abrocitinib, plus topical therapy, was safe and more effective than placebo with topical therapy in adolescents with moderate-to-severe atopic dermatitis (AD) according to clinical trial results.

The JADE TEEN phase 3 study of the Janus kinase (JAK)-1 selective inhibitor was conducted in the Asia-Pacific region, Europe and North America and included Australian patients.

Dr Gary Chan, from Pfizer, and colleagues randomly assigned 285 adolescents with moderate-to